

SOMERSTON CORE EQUITY FUND

INVESTMENT LETTER AS AT 31 MARCH 2024

Portfolio Objectives: To grow capital over the medium term by investing in a concentrated portfolio of high quality companies and to outperform global equities over the economic cycle.

Strategy: We use a fundamental bottom-up approach to identify attractive investment opportunities. We have a 5-year investment horizon. We focus our investments in 15 to 25 high quality companies. We invest in companies that demonstrate strong governance, high profitability, low capital intensity, strong economic moats, and low business risk. We invest globally, without sector/geographic restrictions.

Performance: The Core Equity Fund rose by +1.7% in the month and rose by +7.8% over the last three months. The reference index rose by +2.6% during the month and rose by +11.6% over the last three months.

Performance US0 (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2017				1.2	5.4	-0.2	0.4	-0.1	1.9	1.8	-1.8	2.1	10.9
2018	6.2	-4.6	-1.9	0.4	1.2	1.2	4.3	1.3	0.4	-8.5	2.7	-9.0	-7.2
2019	6.2	4.2	3.3	3.8	-4.0	5.7	0.6	0.8	-1.6	1.3	5.1	2.5	31.1
2020	0.9	-7.3	-14.3	12.5	5.8	2.6	4.4	5.5	-3.4	-3.8	9.7	2.9	13.0
2021	-0.6	1.7	3.3	5.0	0.2	3.4	3.1	2.2	-5.1	6.3	-1.6	2.9	22.2
2022	-8.3	-4.8	4.4	-9.4	-0.2	-8.8	10.4	-4.5	-8.6	6.6	4.7	-4.8	-23.1
2023	2.2	-3.8	5.3	1.8	-1.6	4.7	3.7	-1.1	-5.5	-2.8	8.9	4.6	17.0
2024	2.6	3.3	1.7										7.8

Total return since 2017: 80.5%

Geographical Allocation

Region	% Fund
North America	60.7%
Europe	39.3%

Sector Allocation

Sector	% Fund
Information Technology	24.6%
Health Care	24.3%
Consumer Discretionary	11.5%
Industrials	10.8%
Financials	10.8%
Consumer Staples	9.3%
Communication Services	8.8%

Top Ten Holdings

Name	% Fund
LVMH	10.7%
Mastercard Inc	8.1%
Alphabet Inc	6.3%
Assa Abloy AB-B	6.1%
Microsoft Corp	5.6%
Diageo PLC	5.0%
UnitedHealth Group Inc	4.3%
ASML Holding NV-NY Reg SHS	4.1%
SGS SA	3.9%
EssilorLuxottica SA	3.8%
Total for Top Ten	57.8%

This factsheet shows the performance of Somerson's "Core Equity Strategy" from 31 March 2017 to 30 September 2023 then the Somerston Core Equity Fund from its launch on 02 October 2023.

Activity

During the period the Fund initiated positions in Nvidia, Meta, Eli Lilly, Novo Nordisk, Visa and Synopsys. The Fund entirely divested from Estee Lauder.

Top contributors were LVMH (+1.9%), ASML (+1.8%) and Mastercard (+1.0%). The largest detractors were Adobe (-0.6%), Estee Lauder (-0.5%) and Apple (-0.5%).

During the quarter we have been opportunistically taking advantage of share price strength to raise cash and at quarter end 6.9% of the Fund was allocated to cash. We look for opportunities to deploy this.

Commentary

ASML was a strong contributor to performance during the quarter, with the stock returning 28.4%. **ASML's** importance in the AI industry is clear; it is the only company with the capabilities of producing the EUV technology necessary to manufacture advanced chips. **ASML** reported a strong quarter in late January, which saw the share price jump to an all-time-high. This high has since been surpassed, and we have grown more cautious of the company's valuation. We therefore trimmed the position and invested the proceeds in **Synopsys**. Like **ASML**, **Synopsys** is a 'picks-and-shovels' play on the semiconductor industry. The US-based company develops electronic design automation (EDA) software, which is used in the entire chip design process. The company also owns and licenses semiconductor intellectual property (IP) that chip designers rely on. The combination of software sales and licensing revenue gives the company an attractive recurring revenue profile and the attributes of a 'quality compounder'. We see several important industry trends that should support growth at **Synopsys**. These include the growing prevalence of in-house chip design leading to additional software demand, and increasingly advanced chip designs requiring greater IP spending.

Intuitive Surgical was a strong performer for the Fund, up 18.3% in the quarter. In March, **Intuitive Surgical** received FDA approval for the company's fifth-generation robotic system, da Vinci 5. The product roll out will be gradual but is instrumental in increasing the addressable market of da Vinci procedures. The investment case for Intuitive Surgical is compelling; robotic assistance in surgery can bring significant cost and performance benefits yet remains significantly underpenetrated. It is the market leader in its field, however, despite these merits, in our view, the stock remains expensive. For this reason, we have been active in taking profits and will wait to take advantage of potential future weakness.

During the quarter we completely sold our position in **Estee Lauder**. Historically, the company has been a strong performer, but has recently faced a number of headwinds due to demand weaknesses in China and a misallocation of inventory that built up during the pandemic. We sold the position and invested the proceeds into existing holding, **LVMH**. **LVMH** has since reported an impressive quarter, which saw the shares gain almost 12% on the day of the announcement. Though there had been market fears that overall luxury demand would experience a period of weakness, the reality has been more nuanced. We have seen a bifurcation in the sector, with high-end outperforming aspirational luxury. **LVMH** remains well positioned in this regard, with a portfolio full of some of the most-renowned brands in the industry. The company was the largest position in the Fund and was the top contributor to performance in the quarter.

Adobe was the largest detractor from the Fund during the quarter, with the stock falling 15.4%. As discussed in our January letter, we viewed **Adobe** as one of the likely winners for the AI race, but we started to take profits on valuation grounds. Since then, the market's enthusiasm for **Adobe's** AI offering has come under pressure

following the release of ‘Sora’ from OpenAI, which sparked fears of increased competition in the digital creation space. It was in this context that a solid set of results in mid-March underwhelmed the market for not sufficiently addressing competition concerns. While we consider competition an important risk, we believe the market has been too quick to write off **Adobe**. We note that this quarter showed many areas of strength, such as Firefly adoption rates, and we continue to view management’s AI strategy as sensible. With the stock down c.22% from its early-February high, we felt the market was discounting the risks too heavily and that the valuation looked more attractive. We therefore added to the position following the post-earnings declines.

Apple shares have been under pressure this quarter, falling 10.8%. The US Justice Department sued **Apple** for violating antitrust laws by blocking rivals from accessing hardware and software features on its devices. Simultaneously, there was an EU antitrust announcement on ‘big Tech’ generally. The lawsuits have drawn parallels to the 1998 anti-trust case against Microsoft. **Apple** is a mature company that is able to use its 2 billion user base to provide services with annuity-style revenues. It has a huge net cash balance of \$72 billion and, with free cash flow over \$100 billion, it is priced with a 4% free cash yield. While growth is moderate, we consider the **Apple** ecosystem as attractive. Much of the accusations at **Apple** would potentially compromise the speed, responsiveness and security of the platform and are defensible, whereas other practises may well need refining.

During the quarter, we initiated positions in two prominent pharmaceutical companies, **Novo Nordisk** and **Eli Lilly**. In recent years, both companies have emerged as leaders in the obesity treatment market. The breakthrough GLP-1-based medicines have a significant addressable market. Initial demand has been strong, both companies are currently supply constrained and actively expanding production. The long-term runway for growth is substantial, and we expect to see further adoption as costs come down and an oral version of the treatment becomes available. In addition, GLP-1s are increasingly finding use in non-obesity treatments. In the case of **Novo Nordisk’s** Wegovy, the recent FDA approval for use in treatment of heart disease significantly increases the total addressable market for the drug. Trials are ongoing for use of GLP-1s in treating a range of other conditions, including Alzheimer’s disease, fatty liver disease and sleep apnea. Since purchase, **Novo Nordisk** has returned 14.2% and **Eli Lilly** has returned 3.7%.

Nvidia is a leader in the semiconductor market and has been a holding in the Somerston Technology Fund for several years. The recent release of the Blackwell chip reinforced our view that **Nvidia** is now fundamentally a platform business. We expect revenue to become less cyclical over the years and more reliant on services than products. We have now purchased the name in the Core Equity Fund as we consider the company to have shifted its business model to one which aligns with the mandate of the Fund. The company is not solely reliant on the buildout of AI infrastructure and is primed to deliver compounding revenue from its strength in AI model inference and its growing software business. The share price gains over the past year are significant, yet the earnings improvement has largely matched the stock price. We consider the valuation to be reasonable considering the significant runway for growth. Our current position is modest, but we will look to add when the opportunity is presented. The holding has returned 16.9% since purchase.

We initiated a small position in **Visa** during the quarter. **Visa** plays a vital role in the global payment ecosystem through its position as a major credit and debit card network. The business has significant barriers to entry, which protect high margins and attractive returns on capital. We are positive on the long-term growth outlook for card networks due to the further scope for the digitisation of global payments, particularly in the business-to-business space. The Fund also holds a position in fellow card network **Mastercard**, which was a top contributor during the quarter.

Meta was purchased due to its impressive execution in advertising and its strategic intention in artificial intelligence. The digital ads industry had a tough 2023 with ad prices weak across the sector, yet **Meta** was a

standout from the pack. This is particularly encouraging considering the changes to **Apple's** IDFA policy, and TikTok's share gains which posed a material headwind to the company. In our view this strength clearly demonstrates **Meta's** effective deployment of AI technologies to improve the underlying performance of its advertising platform. **Meta** has acquired significant AI infrastructure and intends to provide a platform for AI applications accessible to its 4 billion installed user base. We believe the company has significant scope for further growth in the coming years.

Nick Wakefield

DISCLAIMER

Any information in this Document may not be suitable for all investors. Investors must make their own investment decisions using their own independent advisors and reviewing relevant offering material (including the Final Offering Document). Any investment decisions must be based upon an investor's specific financial situation and investment objectives and should be based solely on the information in the relevant offering material.

The Fund's manager, Somerston Asset Management Limited (the "Manager") believes the information contained in this Document to be reliable but does not warrant its accuracy or completeness. The information contained herein is preliminary in nature and is not and does not purport to be complete. Any estimates contained herein may be subject to change without notice. No guarantee or representation is made that the investment program set out in this Document, including, without limitation, any investment objectives, diversification strategies, or risk monitoring goals, will be successful, and investment results may vary substantially over time. Investment losses may occur from time to time. Nothing herein is intended to imply that the Manager's investment methodology may be considered "conservative", "safe", "risk free" or "risk averse".

No person, including (without limitation) any of the members, shareholders, directors, officers, partners, employees or advisers of the Manager or its associates, accepts any liability whatsoever (whether direct, indirect, incidental, special, consequential, punitive or otherwise) for any loss arising from any use of the information, opinions or other statements contained herein or otherwise arising in connection therewith (including in the case of negligence, but excluding any liability for fraud) and, accordingly, liability is disclaimed by all such persons to the maximum extent permitted by applicable law or regulation.

NO INVESTMENT ADVICE

The information contained herein does not constitute advice and should not be relied upon for any purpose. No approvals have been given by the Jersey Financial Services Commission in respect of the contents of this Document or the circulation of any offering document in relation thereto.

The information contained herein is not intended to influence you in making any investment decisions and should not be considered as advice or a recommendation to invest. This Document is for information only and provision of this Document does not in itself constitute any kind of service provided by the Manager. Furthermore, this Document does not purport to describe all of the risks associated with investment or the other matters described herein. Income from or the price or value of any financial instruments may rise or fall.

Somerston Asset Management Limited is regulated by the Jersey Financial Services Commission.

WARNING

Past performance is not indicative or a guarantee of future results. No assurance can be made that profits will be achieved or that substantial losses will not be incurred